
NYSEHealthcareMedical - Care Facilities
Latest quote
$20.44
+$0.31 · +1.54%
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
Previous close
$20.44
+$0.31 · +1.54%
Regular session · ET · Market data may be delayed.
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
Day range
Current $20.44
52-week range
Current $20.44
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
89
Deep Value
Sentiment
48
Mixed
Risk
29
Moderate Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
Day range
Current $20.44
52-week range
Current $20.44
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 19.63B EUR | 19.34B EUR | 19.45B EUR | 19.4B EUR | 17.62B EUR |
| Cost of goods sold | 14.6B EUR | 14.58B EUR | 14.53B EUR | 14.5B EUR | 12.85B EUR |
| Gross profit | 5.03B EUR | 4.76B EUR | 4.93B EUR | 4.89B EUR | 4.77B EUR |
| Research and development | 157.98M EUR | 183.49M EUR | 231.97M EUR | 228.62M EUR | 220.78M EUR |
| Selling, general, and administrative | 3.03B EUR | 3.14B EUR | 3.2B EUR | 3.17B EUR | 2.77B EUR |
| Operating expenses | 3.2B EUR | 3.29B EUR | 3.56B EUR | 3.38B EUR | 2.92B EUR |
| Interest income | 69.61M EUR | 71.58M EUR | 88.22M EUR | 67.66M EUR | 73.17M EUR |
| Interest expense | 384.41M EUR | 407.04M EUR | 424.64M EUR | 360.14M EUR | 353.6M EUR |
| Depreciation and amortization | 1.5B EUR | 1.74B EUR | 1.75B EUR | 1.84B EUR | 1.62B EUR |
| Operating income | 1.83B EUR | 1.47B EUR | 1.37B EUR | 1.51B EUR | 1.85B EUR |
| Net income | 978.37M EUR | 537.91M EUR | 499M EUR | 673.41M EUR | 969.31M EUR |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Cash distributions grouped by calendar year; partial years are marked.
$0.815
2025 complete year-0.5% since 2021
2026 partial: $0.8644
$0.8193
2,021
$0.7086
2,022
$0.6049
2,023
$0.6428
2,024
$0.815
2,025
$0.8644
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 22, 2026 | $0.8644Annual | May 22, 2026 | Jun 8, 2026 |
Dividend | May 23, 2025 | $0.815Annual | May 23, 2025 | Jun 6, 2025 |
Dividend | May 17, 2024 | $0.6428Annual | May 20, 2024 | Jun 3, 2024 |
Dividend | May 17, 2023 | $0.6049Annual | May 18, 2023 | Jun 1, 2023 |
Dividend | May 13, 2022 | $0.7086Annual | May 16, 2022 | May 27, 2022 |
Dividend | May 24, 2021 | $0.8193Annual | May 25, 2021 | Jun 7, 2021 |
Ex-dividend May 22, 2026
$0.8644
Annual
Record May 22, 2026 · Payment Jun 8, 2026
Ex-dividend May 23, 2025
$0.815
Annual
Record May 23, 2025 · Payment Jun 6, 2025
Ex-dividend May 17, 2024
$0.6428
Annual
Record May 20, 2024 · Payment Jun 3, 2024
Ex-dividend May 17, 2023
$0.6049
Annual
Record May 18, 2023 · Payment Jun 1, 2023
Ex-dividend May 13, 2022
$0.7086
Annual
Record May 16, 2022 · Payment May 27, 2022
Ex-dividend May 24, 2021
$0.8193
Annual
Record May 25, 2021 · Payment Jun 7, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Pzena U.S. Large Cap Value ETFPZLV2.59M3.70%69.2M USD0.60%$30.54+0.77%
Avantis International Equity ETFAVDE1.45M0.01%18.31B USD0.23%$82.46-2.61%
iShares Flexible Equity Active ETFBFLX1.06M0.04%2.51B USD0.40%$22.9084-3.83%
ActivePassive International Equity ETFAPIE783.85K0.08%1.02B USD0.45%$34.50-3.28%
Alpha Architect US Equity 5 ETFAAUD400K0.15%265.17M USD0.11%$48.0519-3.47%
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV285.23K0.97%29.45M USD0.54%$27.84770.00%
ETF Opportunities Trust - Cultivar ETFCVAR279.03K0.61%46M USD0.87%$30.87070.00%
Dimensional - International Core Equity Market ETFDFAI70.78K0.00%17.21B USD0.18%$38.45-2.51%
Pzena U.S. Large Cap Value ETFPZLV
Avantis International Equity ETFAVDE
iShares Flexible Equity Active ETFBFLX
ActivePassive International Equity ETFAPIE
Alpha Architect US Equity 5 ETFAAUD
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV
ETF Opportunities Trust - Cultivar ETFCVAR
Dimensional - International Core Equity Market ETFDFAIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.